Clinical Efficacy and Safety of <b><i>Artesimia annua</i></b>-Sublingual Immunotherapy in Seasonal Allergic Rhinitis Patients Based on Different Intervention Time

This study proved that A. annua-SLIT can provide equivalent efficacy and safety for SAR patients under the circumstance of accepting the pre-seasonal treatment of 8-9 or 12-13 weeks, regardless of monosensitization or polysensitization.